Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): (Q56449002)
Jump to navigation
Jump to search
article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): |
article |
Statements
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial (English)
Pierre-Marie Girard
José R Arribas
Roland Landman
Judit Pich
Josep Mallolas
María Martínez-Rebollar
Francisco X Zamora
Manuel Crespo
Daniel Podzamczer
Fernando Dronda
José A Iribarren
Pere Domingo
Marta Montero
Laurence Weiss
José M Gatell
Vicente Estrada
Joaquín Portilla
Federico Pulido
Hernando Knobel
André Cabié
OLE/RIS-EST13 Study Group